Grace Therapeutics (GRCE) 10% Owner Inc. Buys $46K of Stock

Opaleye Management Inc. purchased 23,485 shares of Grace Therapeutics, Inc. (GRCE) on October 15, 2026. The 10% owner disclosed the purchase in a Form 4 filing with the Securities and Exchange Commission. The shares were acquired at a price of $1.95 each, for a total value of $45,685.37.

Inside Opaleye Management's Grace Therapeutics Trade

The transaction lifted Opaleye Management's holdings by a 0.81% change in its overall stake, bringing its total ownership to 2,908,007 shares. The trade followed several earlier purchases by the same entity earlier in October 2026. Grace Therapeutics shares closed at $1.95 on the transaction date.

Other Institutional Activity in Grace Therapeutics

Other institutional investors have also adjusted their positions in the biotech firm. Cerity Partners LLC held steady with 849,055 shares valued at $1,604,713. Eversept Partners, LP grew its holdings by 16,268 shares, a 2.1% increase ending with 772,900 shares worth about $1,460,780. Citadel Advisors Llc added 250,999 shares, a 254.2% jump to reach 349,740 shares valued at $661,008. Maven Securities Limited grew its stake by 100,000 shares, a 100.0% increase resulting in 200,000 shares worth $377,999. Birchview Capital, LP raised its position by 70,000 shares, a 140.0% gain to hold 120,000 shares valued at $226,799.

Grace Therapeutics, Inc. Stock Down 3.1%

Grace Therapeutics recently traded around $1.89 as of October 17, 2026, sitting down about 3.1% since the trade date when the stock closed at $1.95. The shares sit below both their 50-day and 200-day moving averages, and well below the 52-week high of $5.18 while trading slightly above the 52-week low of $1.79.

Recent Earnings

The biotechnology company reported a trailing-twelve-month net margin of 0.0% and a return on equity of -36.2%. The firm posted an earnings per share of -$1.17.

Insider Buying and Selling at Grace Therapeutics, Inc.

Opaleye Management has been active in accumulating shares throughout October 2026. The firm bought 60,490 shares on October 5, 5,340 shares on October 9 at $2.04 per share, 7,215 shares on October 12 at $2.02 per share, and 14,632 shares also on October 12.

About Grace Therapeutics

Grace Therapeutics, Inc. is a Princeton, New Jersey-based biopharmaceutical company focused on developing treatments for rare and orphan diseases in Canada. Its lead candidate is GTX-104, an injectable formulation designed to treat aneurysmal subarachnoid hemorrhage.

Bottom Line

Opaleye Management continues to build its position in Grace Therapeutics with regular open-market purchases. Investors will monitor future SEC filings to track further ownership updates from major stakeholders.